JANX Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 3.32%, SMA50 0.1%, SMA200 -37.44%). The stock’s 14-day RSI is 50.62 (neutral), while the ATR of 0.62 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -60.95% below its high and over 13.86% above its low. Average 10-day trading volume of 657.26 thousand shares is below the 3-month average of 1.04 million, indicating normal recent market interest.

Janux Therapeutics, Inc. has 60.09 million shares outstanding. The public float is 44.97 million shares, elevated short interest at 21.29% of float. This equals 8.73 million shares. The short ratio is 10.83 days. Institutional investors hold 117.75% of the float. Insiders own 6.59%. RA CAPITAL MANAGEMENT, L.P. holds 10.14 million shares, Bregua Corp has 3.75 million shares and Reardon Tighe has 633.67 thousand shares. Over the past six months, insider transactions show net selling. They sold 25.13 thousand shares across 8 transactions.

Janux Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$3.75. This means the shares are trading below this model’s fair value.

Janux Therapeutics, Inc. (NASDAQ:JANX) closed at $13.15 USD, losing -$0.47 (-3.45%) from the previous close of $13.62. The stock is currently mid-range between its 52-week high and low $12.12 and $35.34. With a market capitalization of about $801.94 million, Janux Therapeutics, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.52). Key stats such as the average daily volume over the past year has been around 1.03 million shares, in line with its 52-week average. Headquartered in San Diego, CA, Janux Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO David Alan Campbell, the company employs approximately 91 people and listed since June 11, 2021. Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies.

Janux Therapeutics, Inc. generated EPS of -$1.68 over the past year. Five-year average earnings growth is -67.9%. The latest quarter delivered EPS of -$0.39. The next quarter is forecast at -$0.62. Next year's EPS is expected at -$13.64. Analyst sentiment is bullish. Analyst rating data shows there are 10 Strong Buy ratings, 11 Buy ratings, 2 Hold ratings, 0 Sell rating and 1 Strong Sell ratings. Price targets range from $200.00 to $12.00. The high target offers 1420.91% upside. The low target suggests -8.75% downside. The mean target is $59.67. This offers 353.76% upside. Janux Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 07, 2026, missed forecasts by -25.03%. The prior quarter beat by -21.54%. Over the last six quarters, Apple has recorded several small beats. These include -26.53% in February 27, 2025.

Our AI price prediction model suggests that Janux Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -7.22%, with price expected at $12.20 by June 24, 2026, within a range of $11.82 to $12.60 3-Month Outlook: Projected fall of -38.4%, reaching $8.10 by September 08, 2026, with a range of $6.25 to $9.50. 1-Year Outlook: Projected loss of -62.89%, with price at $4.88 by June 10, 2027, within a range of $0.00 to $0.00.

Janux Therapeutics, Inc. (NASDAQ:JANX) shares are flat -4.71% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Janux Therapeutics, Inc. trading at a premium to the broader market with a P/E of -7.16. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $64.80, suggesting 392.78% upside. Our AI forecast model points to short-term weakness (-7.22% over two weeks), a medium-term fall (-38.4% over three months), and a longer-term loss (-62.89% over one year), with expected trading ranges indicating moderate volatility.

Janux Therapeutics, Inc. trades at a P/E ratio of -7.16, slightly below the S&P 500 average, with a price-to-sales ratio of 36.93 and a price-to-book ratio of 0.87 suggesting the stock is closer to book value. The P/FCF stands at -10.17, also above market averages.